You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
再鼎醫藥(09688.HK)與Blueprint及Karuna簽訂授權協議
阿思達克 11-10 09:17
再鼎醫藥(09688.HK)公布,向美國證券交易委員會呈交表格8-K,以報告公司的全資附屬再鼎醫藥(上海)有限公司與Blueprint Medicines Corporation已於2021年11月8日訂立許可及合作協議,公司獲得於中國內地、澳門、香港及台灣地區開發及商業化BLU-701及BLU-945以及其若干其他形式、包括備用複合物的權利。根據協議條款,公司將向Blueprint支付2,500萬美元的預付款,另加於達到指定的臨床、註冊及銷售里程碑後最高合共5.9億美元的里程碑付款。Blueprint亦將有權根據其授權區域內授權產品的年度銷售淨額按低至中十位數的分級的百分比率收取若干特許權使用費,但於特定情況下可作出調減。 另外,公司亦與Karuna Therapeutics, Inc.訂立授權協議,公司與Karuna同意於中國內地、澳門、香港及台灣地區合作開發KarXT,取得於Karuna授權區域開發、生產及商業化KarXT的獨家授權。根據Karuna協議的條款,公司將向Karuna支付3,500萬美元的預付款,另加於達到指定的臨床、註冊及銷售里程碑後最高合共1.52億美元的里程碑付款。Karuna亦將有權根據其授權區域內授權產品的年度銷售淨額按低至高十位數的分級百分比率收取若干特許權使用費,但於特定情況下可作出調減。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account